Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up – Time to Buy?

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) gapped up prior to trading on Thursday . The stock had previously closed at $23.33, but opened at $24.45. Ascentage Pharma Group International shares last traded at $24.45, with a volume of 303 shares traded.

Analyst Ratings Changes

Several research analysts recently commented on AAPG shares. Lucid Cap Mkts raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th. Oppenheimer initiated coverage on shares of Ascentage Pharma Group International in a research note on Thursday, December 4th. They set an “outperform” rating and a $45.00 price target for the company. Truist Financial set a $51.00 price objective on Ascentage Pharma Group International in a research note on Monday, November 24th. Piper Sandler began coverage on Ascentage Pharma Group International in a report on Wednesday, November 5th. They set an “overweight” rating and a $48.00 price objective on the stock. Finally, Rodman & Renshaw began coverage on Ascentage Pharma Group International in a report on Tuesday, January 13th. They issued a “buy” rating and a $48.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. Based on data from MarketBeat, Ascentage Pharma Group International has an average rating of “Buy” and an average price target of $48.40.

Ascentage Pharma Group International Stock Down 1.2%

The business’s 50 day moving average is $27.84 and its 200 day moving average is $34.44. The company has a quick ratio of 1.53, a current ratio of 1.54 and a debt-to-equity ratio of 1.31.

Institutional Investors Weigh In On Ascentage Pharma Group International

A number of institutional investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Ascentage Pharma Group International during the 3rd quarter worth approximately $96,000. ABC Arbitrage SA purchased a new position in Ascentage Pharma Group International in the third quarter worth $204,000. Chevy Chase Trust Holdings LLC acquired a new position in shares of Ascentage Pharma Group International during the second quarter worth $227,000. Citadel Advisors LLC acquired a new position in shares of Ascentage Pharma Group International during the third quarter worth $383,000. Finally, Hsbc Holdings PLC purchased a new stake in shares of Ascentage Pharma Group International during the 2nd quarter valued at $391,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.